{"id":4963,"date":"2023-04-28T11:08:14","date_gmt":"2023-04-28T09:08:14","guid":{"rendered":"https:\/\/www.medincell.com\/teva-and-medincell-announce-fda-approval-of-uzedy-risperidone-extended-release-injectable-suspension-a-long-acting-subcutaneous-atypical-antipsychotic-injection-for-the-treatment-of-schiz\/"},"modified":"2024-03-22T10:30:48","modified_gmt":"2024-03-22T09:30:48","slug":"teva-and-medincell-announce-fda-approval-of-uzedy-risperidone-extended-release-injectable-suspension-a-long-acting-subcutaneous-atypical-antipsychotic-injection-for-the-treatment-of-schiz","status":"publish","type":"post","link":"https:\/\/www.medincell.com\/fr\/teva-and-medincell-announce-fda-approval-of-uzedy-risperidone-extended-release-injectable-suspension-a-long-acting-subcutaneous-atypical-antipsychotic-injection-for-the-treatment-of-schiz\/","title":{"rendered":"Teva et MedinCell annoncent l’approbation par la FDA am\u00e9ricaine de UZEDY\u2122 (risperidone), un antipsychotique sous forme de suspension injectable sous-cutan\u00e9e \u00e0 lib\u00e9ration prolong\u00e9e pour le traitement de la schizophr\u00e9nie chez l’adulte"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"link","meta":{"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"0","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"itsec_x_frame_options":"","footnotes":""},"categories":[37,38,39,29,43],"tags":[44],"class_list":["post-4963","post","type-post","status-publish","format-link","category-home-fr","category-investors-fr","category-news-fr","category-non-classifiee","category-uzedy-fr","tag-2023-fr","post_format-post-format-link"],"_links":{"self":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/posts\/4963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/comments?post=4963"}],"version-history":[{"count":0,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/posts\/4963\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/media?parent=4963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/categories?post=4963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medincell.com\/fr\/wp-json\/wp\/v2\/tags?post=4963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}